An Italian Approach to Postmarketing Monitoring: Preliminary Results From the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) Project on the Safety of Lopinavir/Ritonavir
Authors:
- Paolo BonfantiPBPaolo Bonfanti
- Canio MartinelliCMCanio Martinelli
- Elena RicciERElena Ricci
- Silvia CarradoriSCSilvia Carradori
- Giustino ParrutiGPGiustino Parruti
- Orlando ArmignaccoOAOrlando Armignacco
- Carlo MagnaniCMCarlo Magnani
- Tiziana QuirinoTQTiziana Quirino
- 1 July 2005
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 39 (3) , 317-320
Abstract
The SCOLTA project (Surveillance Cohort Long-term Toxicity Antiretrovirals) is a system for online surveying of adverse reactions to recently commercialized antiretroviral drugs and a “sentinel” for unexpected and late adverse reactions arising during any antiretroviral treatment (available at: http://www.cisai.info). To date, 25 Italian departments of infectious diseases have participated at the project. The New Drugs Project is a prospective, multicenter, observational pharmacovigilance study involving 1 cohort of patients for each new drug. All patients who were consecutively started on lopinavir (LPV), tenofovir (TDF), peginterferon (IFN), atazanavir (ATZ), enfuvirtide (T-20), and tipranavir (TPV) were enrolled. All grade III or IV adverse events (according to the AIDS Clinical Trials Group definitions) are reported on the web site. The Unexpected Events Project identifies unexpected adverse reactions during treatment and reports them. This paper presents the preliminary findings for the New Drugs Project. Between October 1, 2002, and March 30, 2004, 1184 patients were enrolled. The lopinavir/ritonavir (LPV/r) cohort comprises 703 patients, the TDF cohort 585, IFN 35, ATZ 95, T-20 10, and TPV 8. So far 100 grades III and IV adverse events have been reported, 73 in the LPV/r group. In this cohort the rate of adverse events per 100 person-years was 14.2 on the basis of all patients treated, 9.8 for treatment-naive patients, and 15 for treatment-experienced patients. These findings, though preliminary, show that this data collection method gives timely real-life information from which to assess the impact of short- and long-term toxicity of new antiretroviral drugs.Keywords
This publication has 6 references indexed in Scilit:
- ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week resultsAIDS, 2001
- Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996